This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical Services (WST) is likely to have gained from continued strength in high-value product sales in Q2.
3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend
by Sriparna Ghosal
Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Earnings Preview: West Pharmaceutical Services (WST) Q2 Earnings Expected to Decline
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here's Why You Should Retain Integer Holdings Stock for Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Allscripts Extends Strategic Partnership With Microsoft
by Zacks Equity Research
Allscripts (MDRX) extends partnership with Microsoft that can help transform healthcare with smarter technology, thereby improving patient outcomes.
West Pharmaceutical (WST) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
4 Best MedTech Stocks to Combat Coronavirus Crisis on Strong ROE
by Debanjana Dey
Here are some MedTech stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.
BD Collaborates With BARDA to Combat Coronavirus Crisis
by Zacks Equity Research
Becton, Dickinson (BDX) forms a strategic public-private partnership with BARDA to help the U.S. government in its efforts to fight the COVID-19 pandemic and future pandemics.
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
by Zacks Equity Research
Baxter (BAX) receives FDA approval for Altapore Shape that will provide surgeons versatile options to advance the art of healing and boost clinical outcomes during a surgery.
Jobless Claims Hit 4-Month Low in Early July: An Analysis
by Zacks Equity Research
Jobless claims drops with the relaxation of lockdowns and the gradual reopening of businesses. Early July numbers better expectations, signalling the restoration of a flagging coronavirus-stung economy.
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
BD Receives EUA for New Antigen Test to Combat COVID-19
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for a rapid, point-of-care, antigen test to detect SARS-CoV-2 in 15 minutes.
Zacks.com featured highlights include: Teekay Tankers, Tesla, NextEra Energy, Nice and West Pharmaceutical Services
by Zacks Equity Research
Zacks.com featured highlights include: Teekay Tankers, Tesla, NextEra Energy, Nice and West Pharmaceutical Services
Here's Why You Should Invest in OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to benefit from lucrative prospects in RAYALDEE and BioReference platforms.
Luminex Boosts Product Portfolio With New xMAP Technology
by Zacks Equity Research
Luminex (LMNX) commences rollout of new xMAP INTELLIFLEX Systems, which will expand its xMAP Technology.
Jobs Market Strengthening Fast: 4 Sector ETFs & Stocks to Buy
by Sanghamitra Saha
The U.S. economy unexpectedly added 4.8 million jobs in June, breezing past economists??? expectations of job gains of 2.9 million.
5 Low Leverage Stocks to Buy Amid Coronavirus-Led Debacle
by Zacks Equity Research
Investors should know how much debt a company owns, because the higher the degree of financial leverage, higher is the interest payment for the capital borrowed.
Sustainable Investment Forms Part of the New Normal: 5 Picks
by Sreoshi Bera
ESG policies and practices yielded positive outcomes during the coronavirus slump. Also, millennials-driven sustainable investing trend will continue post-pandemic.
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
by Zacks Equity Research
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
by Zacks Equity Research
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Masimo's New Solution to Reduce Opioid Withdrawal Symptoms
by Zacks Equity Research
Masimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Allscripts (MDRX) continues to benefit from lucrative deals and strong prospects in Sunrise EHR. However, margin contraction remains a woe.